Compare Roundhill Magnificent Seven ETF (MAGS) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Roundhill Magnificent Seven ETF vs Novartis AG — how do they compare? Roundhill Magnificent Seven ETF trades at $68.7, while Novartis AG trades at $152.33 (market cap $295.37B). The key difference: Novartis AG pays a 3.07% dividend while Roundhill Magnificent Seven ETF pays none, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| MAGS | NVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $70.94 | $168.62 |
52-Week Low | $55.39 | $119.31 |
Market Cap | — | $295.37B |
Enterprise Value | — | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MAGS trades at $69.07, up 0.71% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights underperformance versus the S&P 500 and concerns over AI spending pressure on big tech balance sheets. The ETF has gained 181% since launch but faces challenges from equal-weighted concentration in the Magnificent Seven stocks.
The outlook is mixed: technical strength supports near-term upside, but fundamental risks from high AI capital expenditure and shifting investor sentiment toward broader market exposure pose headwinds. Investment opportunity hinges on AI revenue growth outpacing costs, while key risks include sector rotation and valuation compression.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
